Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Fasching, Peter A; Jud, Sebastian M; Hauschild, Maik; Kümmel, Sherko; Schütte, Martin; Warm, Matthias; Hanf, Volker; Grab, Dieter; Krocker, Jutta; Stickeler, Elmar; Kreienberg, Rolf; Müller, Thomas; Kühn, Thorsten; Wolf, Christopher; Kahlert, Steffen; Paepke, Stefan; Berghorn, Michael; Muth, Mathias; Baier, Monika; Wackwitz, Birgit; Schulz-Wendtland, Rüdiger; Beckmann, Matthias W; Lux, Michael P 
Titel:
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. 
Abstract:
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL).Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical respon...    »
 
Zeitschriftentitel:
BMC Cancer 
Jahr:
2014 
Band / Volume:
14 
Seitenangaben Beitrag:
66 
Sprache:
eng 
TUM Einrichtung:
Frauenklinik und Poliklinik